editor
leeflang
multiplex
pcr
pointofcar
test
respiratori
viru
infect
b
r
c
object
provid
summari
evid
diagnost
accuraci
three
multiplex
pcr
system
mpcr
dbiofir
filmarray
rp
filmarray
nanospher
verigen
test
verigen
holog
genprob
prodess
assaysdon
detect
viral
respiratori
infect
method
comprehens
search
juli
conduct
medlin
embas
studi
util
filmarray
verigen
prodess
diagnosi
viral
respiratori
infect
summari
diagnost
accuraci
follow
five
virus
calcul
influenza
viru
flua
influenza
b
viru
respiratori
syncyti
viru
human
metapneumoviru
adenoviru
hierarch
summari
receiv
oper
curv
use
estim
viral
detect
perform
per
assay
result
twenti
studi
patient
sampl
elig
analysi
multiplex
pcr
demonstr
high
diagnost
accuraci
area
receiv
oper
characterist
curv
auroc
equal
virus
except
adenoviru
auroc
filmarray
verigen
prodess
assay
enough
data
demonstr
summari
sensit
flua
confid
interv
confid
interv
confid
interv
respect
three
mpcr
compar
term
detect
flua
conclus
point
estim
calcul
elig
studi
show
three
mpcr
filmarray
verigen
highli
accur
may
provid
import
diagnost
inform
earli
identif
respiratori
viru
infect
patient
low
pretest
probabl
flua
three
mpcr
predict
low
possibl
infect
may
justifi
withhold
empir
antivir
treatment
hs
huang
clin
microbiol
infect
acut
respiratori
tract
infect
ari
caus
high
morbid
mortal
among
viral
ari
one
lead
caus
paediatr
geriatr
hospit
clinic
visit
year
season
influenza
caus
hospit
billion
direct
medic
cost
unit
state
specif
popul
eg
immunocompromis
patient
neonat
chronic
pulmonari
diseas
patient
high
complic
mortal
rate
viral
ari
major
concern
moreov
empir
antibiot
commonli
prescrib
patient
viral
ari
lack
rapid
sensit
diagnost
method
nonspecif
symptom
delay
proper
treatment
precipit
antibiot
resist
tradit
diagnost
techniqu
eg
viru
cultur
haemagglutin
inhibit
assay
enzym
immunoassay
direct
fluoresc
antibodi
mainstay
pathogen
detect
howev
method
either
insensit
time
consum
labor
intens
oper
depend
new
technolog
emerg
result
massiv
clinic
demand
melt
curv
analysi
microfluid
devic
nucleic
acid
amplif
technolog
molecular
diagnost
tool
shorter
turnaround
time
higher
sensit
viral
pathogen
addit
allow
detect
broader
panel
virus
coinfect
thu
becom
wide
use
convent
virolog
assay
particular
multiplex
pcr
mpcr
valid
strategi
rapid
detect
precis
identif
larg
number
respiratori
virus
incorpor
sever
primer
within
one
reaction
tube
amplifi
genom
fragment
mani
pathogen
use
mpcr
panel
one
studi
demonstr
increas
diagnost
yield
respiratori
virus
compar
direct
fluoresc
antibodi
cultur
number
us
food
drug
associ
fda
clear
mpcr
avail
today
detect
respiratori
pathogen
pro
con
characterist
three
fdaapprov
mpcr
system
includ
studi
list
tabl
biofir
filmarray
rp
filmarray
respiratori
panel
util
melt
curv
analysi
randomaccess
molecular
test
use
principl
realtim
pcr
verigen
test
base
gold
nanoparticl
technolog
silver
signal
amplif
lastli
holog
genprob
prodess
launch
sever
assay
variabl
run
size
also
util
melt
curv
analysi
limit
multiplex
abil
although
prodess
assay
detect
two
three
virus
time
prodess
assay
still
view
mpcr
three
mpcr
chosen
shorter
turnaround
time
avail
studi
analysi
among
number
fdaapprov
mpcr
also
one
origin
studi
provid
direct
comparison
three
mpcr
gain
insight
optim
diagnost
tool
routin
clinic
use
provid
summari
evid
compar
diagnost
accuraci
filmarray
verigen
holog
genprob
prodess
assay
detect
viral
respiratori
infect
protocol
studi
base
prisma
prefer
report
item
systemat
review
metaanalysi
statement
standard
guidelin
systemat
review
diagnost
test
cochran
collabor
comprehens
search
literatur
conduct
use
two
databas
pubm
incept
april
embas
incept
april
search
term
combin
multiplex
pcr
multiplex
polymeras
chain
reaction
filmarray
verigen
prodess
proflu
profast
proadeno
proparaflu
pro
hmpv
respiratori
tract
infect
respiratori
infect
respiratori
viru
respiratori
tract
diseas
respiratori
diseas
common
cold
influenza
pneumonia
bronchiti
bronchiol
rhinosinus
pharyng
laryng
otiti
media
tonsil
asthma
copd
chronic
obstruct
lung
diseas
detail
search
strategi
provid
supplementari
materi
languag
restrict
appli
search
search
supplement
bibliographi
retriev
fulltext
articl
latest
narr
review
also
contact
author
public
provid
requir
data
updat
search
juli
perform
start
statist
analysi
studi
evalu
perform
fdaapprov
mpcr
system
detect
viral
respiratori
infect
includ
follow
assess
accuraci
one
follow
system
filmarray
nanospher
verigen
holog
genprob
prodess
assay
profast
pro
refer
standard
b
provid
suffici
inform
calcul
sensit
standard
valid
mpcr
system
c
use
mpcr
assay
approv
fda
refer
addit
exclud
review
guidelin
case
report
editori
panel
discuss
letter
note
comment
multipl
public
latest
avail
public
complet
data
patient
group
includ
studi
compar
one
fdaapprov
mpcr
system
refer
standard
use
differ
refer
method
differ
virus
use
differ
sampl
differ
virus
report
prospect
retrospect
sampl
independ
separ
data
set
comparison
three
review
independ
screen
titl
abstract
pubm
embas
disagr
uncertainti
resolv
discuss
data
extract
form
use
includ
studi
two
review
final
data
set
extract
two
author
independ
avoid
bia
form
consist
follow
characterist
studi
type
studi
design
patient
age
patient
inclus
criteria
specimen
type
mpcr
system
use
refer
standard
tabl
tabl
use
calcul
sensit
specif
target
assay
refer
method
viru
cultur
direct
fluoresc
antibodi
group
togeth
univers
recogn
refer
standard
revers
transcript
rt
pcr
refer
commerci
rtpcr
inhous
rtpcr
composit
refer
standard
defin
standard
use
one
compar
assay
discrep
analys
encompass
studi
resolv
discrep
target
assay
compar
assay
bidirect
sequenc
rtpcr
repeat
test
method
studi
also
group
basi
whether
incorpor
filmarray
verigen
holog
genprob
prodess
assay
part
composit
refer
standard
studi
sampl
taken
lower
respiratori
tract
categor
use
upper
respiratori
specimen
children
defin
patient
younger
year
studi
includ
children
adult
popul
categor
mix
qualiti
elig
studi
independ
assess
two
review
use
qualiti
assess
diagnost
accuraci
studi
tool
diagnost
studi
determin
risk
bia
gener
applic
four
domain
report
separ
low
risk
bia
low
concern
regard
applic
judg
low
studi
would
judg
unclear
insuffici
data
interpret
bivari
model
appli
estim
summari
sensit
specif
posit
likelihood
ratio
neg
likelihood
ratio
calcul
summari
sensit
specif
bivari
model
approach
model
logittransform
sensit
specif
simultan
account
inher
neg
correl
sensit
specif
may
aris
due
differ
threshold
differ
studi
addit
bivari
model
could
also
account
betweenstudi
heterogen
analys
except
summari
receiv
oper
characterist
curv
roc
perform
mada
packag
r
softwar
r
foundat
statist
comput
vienna
austria
http
wwwrprojectorg
summari
roc
area
roc
calcul
mida
packag
stata
stata
inc
colleg
station
texa
twosid
p
valu
indic
statist
signific
test
comprehens
search
yield
studi
embas
studi
pubm
inclus
exclus
follow
protocol
updat
search
juli
fig
total
studi
data
set
elig
analysi
encompass
total
patient
sampl
prodess
assay
enough
data
set
quantit
analysi
parainfluenza
viru
analys
insuffici
data
laboratori
characterist
filmarray
rp
verigen
prodess
illustr
tabl
simplifi
summari
characterist
includ
studi
provid
tabl
detail
characterist
key
result
individu
studi
provid
supplementari
materi
none
studi
specif
recruit
adult
approxim
studi
obtain
sampl
children
discrep
analysi
composit
refer
standard
two
commonli
appli
refer
standard
studi
vari
qualiti
qualiti
assess
tool
demonstr
fig
patient
select
domain
studi
clear
patient
recruit
studi
use
refriger
sampl
precollect
without
specifi
origin
sourc
other
avoid
caseecontrol
design
refer
standard
domain
studi
specifi
use
blind
refer
standard
studi
low
qualiti
regard
use
index
test
part
refer
method
other
use
refer
method
sampl
howev
studi
identifi
high
qualiti
flow
time
overal
major
studi
low
concern
regard
applic
overal
suggest
high
ruleout
valu
tabl
provid
point
estim
flub
rsv
hmpv
adenoviru
fig
show
forest
plot
sensit
specif
mpcr
viru
fig
illustr
receiv
oper
characterist
curv
area
receiv
oper
characterist
curv
detect
viru
overal
analys
includ
patient
sampl
mpcr
system
demonstr
high
diagnost
accuraci
auroc
flua
flub
rsv
hmpv
except
adenoviru
auroc
filmarray
rp
verigen
prodess
demonstr
summari
sensit
flua
confid
interv
ci
ci
ci
respect
three
mpcr
compar
term
detect
flua
filmarray
rp
verigen
compar
rsv
detect
although
prodess
found
statist
signific
higher
sensit
filmarray
rp
flub
detect
demonstr
compar
auroc
thu
compar
accuraci
five
respiratori
virus
system
detect
diagnosi
influenza
viru
infect
may
greatest
clinic
impact
basi
studi
overal
mpcr
exhibit
reason
sensit
ci
high
specif
ci
flua
current
clinic
practic
immunoassaybas
rapid
influenza
diagnost
test
wide
use
screen
influenza
infect
although
rapid
influenza
diagnost
test
detect
flua
flub
respiratori
specimen
approxim
minut
sensit
limit
report
previou
metaanalysi
may
give
falseneg
result
prevent
use
reliabl
exclud
diagnost
tool
clinic
practic
furthermor
commonli
use
refer
standard
rtpcr
viru
cultur
may
take
sever
day
yield
result
littl
valu
treatment
decis
metaanalysi
show
mpcr
provid
highli
accur
result
clinic
relev
time
frame
may
potenti
chang
current
diagnost
treatment
practic
flua
infect
result
low
sensit
rapid
influenza
diagnost
test
decis
antivir
treatment
flua
infect
larg
base
clinic
ground
alon
may
lead
overprescript
antiinfluenza
drug
increas
drug
resist
studi
van
wesenbeeck
et
al
clinic
sampl
conclud
filmarray
rp
prodess
better
sensit
flua
verigen
contrari
result
found
three
mpcr
compar
flua
detect
metaanalysi
synthes
data
across
differ
studi
encompass
patient
sampl
may
present
accur
estim
real
situat
although
three
system
compar
accuraci
flua
filmarray
rp
shortest
handson
time
minut
run
time
hour
among
three
mpcr
includ
sampl
prepar
panel
furthermor
reagent
store
room
temperatur
assay
detect
largest
number
target
therefor
filmarray
rp
may
best
choic
emerg
room
influenza
season
less
interest
rapid
diagnost
test
rsv
hmpv
adenoviru
result
lack
specif
treatment
avail
virus
common
practic
support
care
clinic
set
nevertheless
rsv
one
lead
caus
ari
children
immunocompromis
patient
may
caus
sever
complic
therefor
requir
definit
diagnosi
result
reveal
mpcr
highli
sensit
specif
rsv
hmpv
offer
rapid
accur
altern
tradit
method
current
treatment
ribavirin
highrisk
infant
young
children
sever
clinic
trial
novel
rsv
treatment
underway
contrast
adenoviru
filmarray
rp
moder
low
sensit
superior
specif
make
reliabl
rulein
tool
literatur
demonstr
commerci
filmarray
rp
low
sensit
adenoviru
sensit
greatli
improv
commerci
filmarray
develop
later
note
none
includ
studi
specif
report
use
filmarray
knowledg
first
report
perform
compar
metaanalysi
differ
mpcr
platform
differ
virus
provid
detail
comparison
characterist
three
system
also
provid
quantit
accuraci
measur
differ
virus
differ
system
sever
limit
studi
howev
firstli
includ
studi
provid
suffici
detail
regard
version
filmarray
rp
use
premarket
commerci
trace
public
date
contact
filmarray
rp
manufactur
well
author
origin
studi
attempt
confirm
version
filmarray
rp
howev
sensit
analysi
show
clinic
signific
differ
sensit
specif
precommerci
fdaapprov
commerci
assay
data
publish
secondli
includ
studi
retrospect
studi
design
fail
specifi
inclus
criteria
use
previous
store
sampl
patient
unknown
characterist
also
concern
regard
diagnost
review
bia
interpret
result
refer
test
made
knowledg
index
test
result
howev
test
review
bia
highli
unlik
interpret
index
test
mpcr
object
note
five
includ
studi
adopt
caseecontrol
design
tend
give
overestim
accuraci
index
test
addit
result
studi
show
accuraci
three
commerci
mpcr
system
diagnosi
respiratori
viru
infect
whether
equal
strength
therapeut
guidanc
remain
valid
lastli
studi
provid
answer
whether
mpcr
system
improv
outcom
patient
respiratori
viru
infect
compar
clinic
diagnosi
alon
analysi
elig
studi
show
three
commerci
mpcr
systemsdfilmarray
verigen
genprob
prodess
provid
import
diagnost
inform
help
earli
identif
influenza
viru
respiratori
syncyti
viru
adenoviru
hmpv
great
improv
sensit
rapid
diagnosi
influenza
may
potenti
chang
current
mode
diagnosi
manag
howev
system
equal
use
term
inclus
exclus
diagnosi
clinician
interpret
result
basi
likelihood
ratio
pretest
probabl
next
step
would
assess
whether
provis
inform
mpcr
test
modifi
clinic
outcom
